

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Not applicable	<p><i>In vitro</i> and mouse studies identified a series of Ellence-nitric oxide copolymer conjugates that could help treat cancer. In a colorectal cancer cell line, one of the conjugates showed anticancer activity. In cultured endothelial cells and cardiomyocytes, the conjugate had less toxicity than Ellence alone. In mice, the conjugate had good pharmacokinetics and bioavailability compared with Ellence. Next steps include testing the compound in animal tumor models. Pfizer Inc. markets the DNA-intercalating agent Ellence epirubicin to treat breast cancer.</p> <p><b>SciBX 2(38); doi:10.1038/scibx.2009.1434</b> Published online Oct. 1, 2009</p>	Compounds patented by Biopeg Ltd.; unavailable for licensing	<p>Pasut, G. <i>et al. J. Med. Chem.</i>; published online Sept. 18, 2009; doi:10.1021/jm900804m</p> <p><b>Contact:</b> Gianfranco Pasut, University of Padua, Padova, Italy e-mail: <a href="mailto:gianfranco.pasut@unipd.it">gianfranco.pasut@unipd.it</a></p>